[1]杨炜浩,仲斌演,杨 飞,等.经动脉化疗栓塞联合卡瑞利珠单抗及酪氨酸激酶抑制剂治疗中晚期肝细胞癌的安全性及近期疗效[J].介入放射学杂志,2022,31(05):459-464.
 YANG Weihao,ZHONG Binyan,YANG Fei,et al.Transarterial chemoembolization combined with camrelizumab and tyrosine kinase inhibitor for advanced hepatocellular carcinoma: its safety and short-term efficacy[J].journal interventional radiology,2022,31(05):459-464.
点击复制

经动脉化疗栓塞联合卡瑞利珠单抗及酪氨酸激酶抑制剂治疗中晚期肝细胞癌的安全性及近期疗效()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
31
期数:
2022年05
页码:
459-464
栏目:
肿瘤介入
出版日期:
2022-07-19

文章信息/Info

Title:
Transarterial chemoembolization combined with camrelizumab and tyrosine kinase inhibitor for advanced hepatocellular carcinoma: its safety and short-term efficacy
作者:
杨炜浩 仲斌演 杨 飞 沈 健 朱晓黎
Author(s):
YANG Weihao ZHONG Binyan YANG Fei SHEN Jian ZHU Xiaoli.
Department of Interventional Radiology, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province 215006, China
关键词:
【关键词】 肝细胞癌不良事件 联合治疗 化疗栓塞 卡瑞利珠单抗 酪氨酸激酶抑制剂
文献标志码:
A
摘要:
【摘要】 目的 评价动脉化疗栓塞术(TACE)联合卡瑞利珠单抗(Camrelizumab)及酪氨酸激酶抑制剂(TKI)治疗中晚期肝细胞癌(HCC)患者的安全性及有效性。方法 回顾性分析2019年8月至2021年2月接受TACE、Camrelizumab、TKI联合治疗的33例HCC患者的临床资料。根据美国国家癌症研究所常见不良事件评价标准(CTCAE)5.0版记录出现不可接受的毒性或疾病进展前各类不良事件发生情况;根据实体瘤改良反应评估标准(mRECIST)评估肿瘤反应,包括完全缓解(CR)、部分缓解(PR)、疾病稳定(SD)和疾病进展(PD),并计算肿瘤客观缓解率(ORR)、疾病控制率(DCR);统计分析无进展生存期(PFS)及至疾病进展时间(TTP)。结果 33例患者的中位随访时间为15.1个月(95%CI:9.5~18.0),共29例(87.9%)患者发生了不良事件。主要为肝功能损伤17例(51.5%)、反应性皮肤毛细血管增生症(RCCEP)14例(42.5%)、皮疹13例(39.3%)、甲状腺功能减退12例(36.3%)。有5例(15.2%)患者出现了3级不良事件,主要为肝功能损伤(9.1%)。不良事件导致2例患者TKI减量,1例患者暂停免疫治疗1次,3例患者因无法缓解的严重不良事件而永久停药。33例患者中,4例(12.1%)获得CR,20例(60.6%)获得PR,3例(9.1%)获得SD,ORR为72.7%,DCR为81.8%。中位PFS为 9.2个月(95%CI:5.9~12.5)、中位TTP为7.7个月(95%CI:3.3~12.1)。 结论 TACE联合Camrelizumab及TKI治疗中晚期HCC严重不良事件发生率较低、肿瘤控制率较高、至疾病进展时间延长,有望为中晚期肝癌生存延长提供治疗选择。

参考文献/References:

[1] Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology, 2018, 67: 358- 380.
[2] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69:182- 236.
[3] Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis[J]. Lancet Oncol, 2009, 10: 35- 43.
[4] Kudo M, Arizumi T, Ueshima K, et al. Subclassification of BCLC B stage hepatocellular carcinoma and treatment strategies: proposal of modified bolondi’s subclassification(Kinki criteria)[J]. Dig Dis, 2015, 33: 751- 758.
[5] Wang Q, Xia D, Bai W, et al. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: a multicentre observational study[J]. J Hepatol, 2019, 70: 893- 903.
[6] Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α- fetoprotein concentrations(REACH- 2): a randomised, double- blind, placebo- controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20: 282- 296.
[7] Kudo M, Finn R, Qin S, et al. Lenvatinib versus sorafenib in first- line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non- inferiority trial[J]. Lancet, 2018, 391: 1163- 1173.
[8] Abou- Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma[J]. N Engl J Med, 2018, 379: 54- 63.
[9] Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double- blind, placebo- controlled, phase 3 trial[J]. Lancet, 2017, 389: 56- 66.
[10] Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multi- centre, open- label, parallel- group, randomised, phase 2 trial[J]. Lancet Oncol, 2020, 21: 571- 580.
[11] Yau T, Hsu C, Kim TY, et al. Nivolumab in advanced hepatocellular carcinoma: sorafenib- experienced Asian cohort analysis[J]. J Hepatol, 2019, 71: 543- 552.
[12] Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab as second- line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE- 240: a randomized, double- blind, phase Ⅲ trial[J]. J Clin Oncol, 2020, 38: 193- 202.
[13] Zheng L, Fang S, Wu F, et al. Efficacy and safety of TACE combined with sorafenib plus immune checkpoint inhibitors for the treatment of intermediate and advanced TACE- refractory hepatocellular carcinoma: a retrospective study[J]. Front Mol Biosci, 2020, 7: 609322.
[14] 黄 剑,葛乃建,徐 伟,等. TACE联合卡瑞利珠单抗及甲磺酸阿帕替尼治疗晚期肝细胞癌16例[J]. 介入放射学杂志, 2021, 30:774- 779.
[15] Marinelli B, Cedillo M, Pasik SD, et al. Safety and efficacy of locoregional treatment during immunotherapy with nivolumab for hepatocellular carcinoma: a retrospective study of 41 interventions in 29 patients[J]. J Vasc Interv Radiol, 2020, 31: 1729.e1- 1738.e1.
[16] Petrillo M, Patella F, Pesapane F, et al. Hypoxia and tumor angiogenesis in the era of hepatocellular carcinoma transarterial loco- regional treatments[J]. Future Oncol, 2018, 14: 2957- 2967.
[17] Palmer DH, Malagari K, Kulik LM. Role of locoregional therapies in the wake of systemic therapy[J]. J Hepatol, 2020, 72: 277- 287.
[18] Kudo M, Ueshima K, Ikeda M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation(TACE) plus sorafenib as compared with TACE alone in patients with hepato-cellular carcinoma: TACTICS trial[J]. Gut, 2020, 69: 1492- 1501.
[19] Xue J, Ni H, Wang F, et al. Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy[J]. J Intervent Med, 2021, 4: 105- 113.
[20] Cheng AL, Hsu C, Chan SL, et al. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma[J]. J Hepatol, 2020, 72: 307- 319.
[21] Sun Y, Tan J, Miao Y, et al. The role of PD- L1 in the immune dysfunction that mediates hypoxia- induced multiple organ injury[J]. Cell Commun Signal, 2021, 19: 76.
[22] Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382: 1894- 1905.
[23] Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar(IBI305) versus sorafenib in unresectable hepatocellular carcinoma(ORIENT- 32): a randomised,open- label,phase 2- 3 study[J]. Lancet Oncol, 2021, 22: 977- 990.
[24] Xu J, Shen J, Gu S, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open- label, phase Ⅱ trial[J]. Clin Cancer Res, 2021, 27: 1003- 1011.

相似文献/References:

[1]姚雪松,李 槐.不可手术切除的肝细胞癌的疗效评价标准——改良RECIST标准更可靠[J].介入放射学杂志,2012,(03):177.
 . Therapeutic evaluation criterion of inoperable hepatocellular carcinomas: modified RECIST as a more reliable standard[J].journal interventional radiology,2012,(05):177.
[2]梁茂全,苏洪英. 肝癌化疗栓塞前后甲胎蛋白变化模式的临床意义[J].介入放射学杂志,2012,(04):333.
 .The transformation pattern of serum аfetoprotein after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma: its clinical significance [J].journal interventional radiology,2012,(05):333.
[3]孙 磊,施海彬,刘 圣,等.肝细胞癌肝动脉门静脉分流形成的相关因素分析[J].介入放射学杂志,2012,(03):206.
 ,,et al.The factors related to the formation of arterioportal shunting in patients with hepatocellular carcinomas [J].journal interventional radiology,2012,(05):206.
[4]沈海洋,刘瑞宝,刘 岩,等. 肝右叶前、后段原发性肝癌TACE后VEGF及CD34的表达水平 ;[J].介入放射学杂志,2012,(06):469.
 SHEN Hai- yang,LIU Rui- bao,LIU Yan,et al. The expression levels of vascular endothelial growth factor and CD34 in residual cancerous tissues of primary hepatocellular carcinoma located at anterior and posterior segments of right lobe liver after TACE[J].journal interventional radiology,2012,(05):469.
[5]李晓峰,钱国军,张 磊,等. 微波高功率条件下消融原发性肝癌的初步研究[J].介入放射学杂志,2011,(12):974.
 LI Xiao-feng,QIAN Guo-jun,ZHANG Lei,et al.Microwave ablation with high output power for the treatment of hepatocellular carcinoma: a preliminary study[J].journal interventional radiology,2011,(05):974.
[6]彭辽河,胡晓燕,李 杰,等. 18F-FDG PET/CT显像在肝细胞癌TACE术后残留或复发病灶检出中的应用价值[J].介入放射学杂志,2012,(08):636.
 PENG Liao- he,HU Xiao- yan,LI Jie,et al. Clinical application of 18F- FDG PET/CT imaging in detecting residual lesions or recurrence foci of hepatocellular carcinoma after TACE treatment[J].journal interventional radiology,2012,(05):636.
[7]陆小华,朱小庆,茅国新.肝细胞癌相关单核苷酸多态性的研究进展[J].介入放射学杂志,2013,(06):520.
 LU Xiao? hua,ZHU Xiao? qing,MAO Guo? xin.. Hepatocellular carcinoma?蛳 related single nucleotide polymorphisms: recent advances in research[J].journal interventional radiology,2013,(05):520.
[8]姚雪松,闫 东,曾辉英,等.TACE联合索拉非尼治疗不能手术切除肝细胞癌介入治疗间隔时间的分析[J].介入放射学杂志,2014,(09):769.
 YAO Xue song,YAN Dong,ZENG Hui ying,et al.TACE combined with sorafenib for inoperable hepatocellular carcinoma: analysis of treatment interval[J].journal interventional radiology,2014,(05):769.
[9]姚雪松,闫 东,曾辉英,等. TACE联合索拉非尼治疗不能手术切除肝细胞肝癌50例[J].介入放射学杂志,2013,(05):381.
 YAO Xue? song,YAN Dong,ZENG Hui? ying,et al. Ttransarterial chemoembolization combined with sorafenib for inoperable hepatocellular carcinoma: a clinical analysis of 50 cases[J].journal interventional radiology,2013,(05):381.
[10]赵 松,陈学春,龙清云,等. 经肝动脉化疗栓塞联合射频消融治疗肝细胞癌疗效荟萃分析[J].介入放射学杂志,2013,(11):908.
 ZHAO Song,CHEN Xue? chun,LONG Qing? yun,et al. Transcatheter arterial chemoembolization combined with radiofrequency ablation for the treatment of hepatocellular carcinoma: a systematic review and Meta analysis[J].journal interventional radiology,2013,(05):908.

备注/Memo

备注/Memo:
(收稿日期:2021- 09- 18)
(本文编辑:李 欣)
更新日期/Last Update: 2022-07-19